Protara Therapeutics, Inc. (TARA)

Market Cap	98.20M
Revenue (ttm)	n/a
Net Income (ttm)	-42.05M
Shares Out	20.63M
EPS (ttm)	-2.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,368
Open	4.550
Previous Close	4.550
Day's Range	4.550 - 4.820
52-Week Range	1.595 - 10.480
Beta	1.64
Analysts	Strong Buy
Price Target	22.67 (+376.26%)
Earnings Date	Mar 12, 2025

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutritio...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jesse Shefferman
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: TARA
• Website: https://www.protaratx.com

Analyst Forecast

According to 3 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is $22.67, which is an increase of 376.26% from the latest price.

Price Target

$22.67

(376.26% upside)

Analyst Consensus: Strong Buy